Group 1 - The Shanghai Stock Exchange implemented self-regulatory measures on 146 cases of abnormal trading behaviors, including price manipulation and false declarations, from December 8 to December 12, 2025 [1] - The exchange focused on monitoring stocks with significant volatility, including delisted stocks such as Suwu (600200), *ST Yazhen (603389), HeFu China (603122), and Tianpu Co., Ltd. (605255) [1] - The exchange conducted special investigations on 24 major events of listed companies and reported 3 suspected illegal activities to the China Securities Regulatory Commission [1]

Core Viewpoint - BenQ Hospital (02581.HK) plans to globally offer 67 million shares, with 6.7 million shares for Hong Kong and 60.3 million shares for international distribution, aiming for a price range of HKD 9.34 to HKD 11.68 per share [1][2] Group 1: Company Overview - The company is a private for-profit comprehensive hospital group in mainland China, leveraging operational management experience from Taiwan [1] - Currently operates two private for-profit hospitals and is the largest in the East China region with a market share of 1.0% based on total revenue for 2024 [1] - Ranked seventh among private for-profit comprehensive hospital groups nationwide with a market share of 0.4% [1] - Holds the top position in bed revenue per bed among all private for-profit comprehensive hospital groups in mainland China for 2024 [1] Group 2: Operational Metrics - As of June 30, 2025, the company’s two hospitals have a total construction area of approximately 400,000 square meters and 1,850 registered beds [2] - The hospital group has over 1,000 experienced doctors, including 35 experts from Taiwan and overseas [2] - In 2024, the group expects over 2 million outpatient visits and more than 22,000 inpatient surgeries [2] Group 3: Fundraising and Use of Proceeds - The company has established cornerstone investment agreements totaling USD 39.9 million (approximately HKD 311 million) for share purchases [2] - Assuming a share price of HKD 10.51, the net proceeds from the global offering are expected to be approximately HKD 626 million [3] - The intended use of proceeds includes approximately 74.3% for hospital expansion and upgrades, 16.0% for potential investments and acquisitions, 8.0% for upgrading the "smart hospital" initiative, and 1.8% for working capital and general corporate purposes [3]

Company News - Xinfeng Pharmaceutical is facing prosecution for alleged unit bribery, which may negatively impact its brand reputation and business development [2] - Muxi Co. reported that online investors abandoned the subscription of 20,349 shares, with a total value of approximately 2.13 million yuan [3] - Yonghui Supermarket is undergoing orderly store adjustments, with normal business operations [4] - Central Plaza has authorized management to implement a plan to suspend operations at its Xuzhou store due to ongoing operational difficulties [5] - Dongbai Group's largest shareholder reduced its stake by 2.98% on December 9 [6] - Lens Technology plans to acquire 100% of PMG International to enhance its capabilities in AI computing infrastructure [6] - CATL intends to register and issue bonds not exceeding 10 billion yuan for project construction and working capital [7] - Kweichow Moutai announced a mid-term dividend of 30 billion yuan for 2025, with the record date on December 18 [8] - Wuliangye approved a mid-term dividend of 10.007 billion yuan for 2025, with the record date on December 17 [9] - Century Huatong's subsidiary holds 1,958,870 shares of Moer Thread, which may significantly impact its Q4 net profit [10] - Huayi Brothers reported a debt default of 52.5 million yuan and plans to gradually exit and dispose of some assets [11] - Western Materials' second-largest shareholder reduced its stake by 7.13 million shares from March 5 to December 9 [12] - Guomin Technology plans to change its domestic accounting firm due to regulatory investigations involving its previous auditor [13] Investment & Contracts - China Shipbuilding Special Gas announced an investment of 870 million yuan to build a project for producing high-purity hydrogen sulfide and other electronic gases [14] - Daon Co. plans to acquire 80% of Ningbo Aisikai Synthetic Rubber Co. for 516 million yuan, enhancing its production capabilities [15] - Huasheng Co. intends to purchase 97.4% of AIDC's Yixin Technology for approximately 666 million yuan [16] - Wuhan Tianyuan's subsidiary signed an investment agreement for a total of about 600 million yuan in energy storage projects [17] Shareholding Changes & Buybacks - Qianzhao Optoelectronics' chairman plans to reduce his stake by up to 145,000 shares due to personal financial needs [18] - Zhuangyuan Ranch's major shareholder intends to reduce his stake by up to 3% [19] - Zhili Fang plans to reduce its stake by up to 1.20% [20] - Yingsite's major shareholder plans to reduce its stake by up to 2.22% [21] Operations & Performance - Hefei China reported a consolidated revenue of 628 million yuan for the first 11 months, a decrease of 26.02% year-on-year [22] Contracts & Project Wins - Jicheng Electronics won contracts totaling approximately 215 million yuan from the State Grid [23] Stock Price Fluctuations - Fuzheng Technology's stock experienced abnormal fluctuations, with its controlling shareholder reducing holdings by 1.0429 million shares [24] Other - Kaisheng New Materials has postponed the implementation of its lithium battery project due to market uncertainties [25]

Group 1 - Guizhou Moutai announced a mid-term profit distribution plan for 2025, with a total cash dividend of 300.01 billion yuan, distributing 23.957 yuan per share [1] - CATL plans to register and issue bonds not exceeding 10 billion yuan, with a maturity of up to 5 years, primarily for project construction and working capital [2] - Yonghui Supermarket disclosed a risk warning regarding its stock, indicating potential overheating market sentiment and high speculation risks due to significant price increases [3] Group 2 - Yuntianhua intends to acquire 100% equity of Tianyao Chemical for 36.8858 million yuan, enhancing its fine phosphorus chemical product synergy and market competitiveness [4] - Muxi Co. reported that online investors abandoned the subscription of 20,349 shares, with a total value of approximately 212.97 million yuan [5] - Ningbo Huaxiang plans to acquire 40% equity of Fengmei Power, promoting its transformation in the new energy battery and intelligent chassis sectors [6] Group 3 - Wuhan Tianyuan's subsidiary plans to invest approximately 600 million yuan in two energy storage projects [7] - Wanshun New Materials' subsidiary intends to acquire 100% equity of Eurofoil Luxembourg for 12.3889 million euros, enhancing its market presence in the aluminum foil and sheet industry [9] - Medike plans to introduce strategic investors for its subsidiary, raising 200 million yuan for business expansion [10] Group 4 - Century Huatong's subsidiary holds 7.3121% of Guosheng Capital, which owns 1,958,887 shares of Moer Thread, potentially impacting the company's net profit significantly [11] - Dingyang Technology launched the SPB3000X series of simulators, aiming for large-scale sales while facing market promotion challenges [12] - Baiyun Airport reported a passenger throughput of 7.3228 million in November, a year-on-year increase of 12.58% [13] Group 5 - ST Yigou's subsidiary sold eight subsidiaries, expecting to increase net profit by approximately 992 million yuan [14] - Shennong Development reported a sales revenue of 1.81 billion yuan in November, a year-on-year increase of 15.77% [15][16] - Minhe's sales revenue from broiler chicks increased by 7.75% month-on-month, despite a year-on-year decline [17] Group 6 - Xiaoming's sales revenue from chicken products decreased by 49.73% year-on-year, influenced by market supply and demand dynamics [18] - Hefei China reported a consolidated revenue of 628 million yuan from January to November, a year-on-year decline of 26.02% [19] - Xiantan's chicken product sales revenue increased by 11.63% year-on-year, supported by ongoing project developments [20] Group 7 - Tian Nai Technology's major shareholders plan to reduce their holdings by up to 2.5% [21] - Xingyu Co. intends to repurchase shares worth 200 to 300 million yuan for employee stock ownership plans [22] - Baiao Chemical adjusted its share repurchase price ceiling to not exceed 48.95 yuan per share [23] Group 8 - Jicheng Electronics won contracts totaling approximately 215 million yuan from the State Grid [25] - Ruikemi received a development notice from a well-known flying car company for core component supply [26]

Group 1 - Jicheng Electronics won a total of 15 bids from the State Grid Corporation, with a total bid amount of approximately 215 million yuan, accounting for 8.27% of the company's projected revenue for 2024 [2] - Jianmin Group's chemical generic drug, Ambrutoro Oral Solution, has been approved for market launch by the National Medical Products Administration, aimed at treating cough and wheezing caused by chronic bronchitis and emphysema [3] - Taiji Industry's subsidiary plans to transfer accounts receivable not exceeding 85 million USD to optimize cash flow, with an expected service fee of approximately 285,000 USD [4] Group 2 - Nanjing Pharmaceutical's subsidiary plans to invest 398 million yuan in a modern pharmaceutical logistics expansion project, with a construction period of approximately 35 months [5] - Ruili Kemi received a development notification from a well-known domestic flying car company to supply core components [6] - Ding Tong Technology announced that several executives plan to reduce their holdings by a total of no more than 45,300 shares, representing about 0.032% of the total share capital [7][8] Group 3 - Ninghu Expressway's subsidiary plans to invest no more than 9.033 billion yuan in the construction of the Nanyang Yangtze River Bridge South Connection Project [10] - Wuliangye announced a mid-term profit distribution plan for 2025, proposing a cash dividend of 25.78 yuan per 10 shares, totaling approximately 10 billion yuan [12] - Beixin Road and Bridge's subsidiary won a bid for a project worth 180 million yuan [14] Group 4 - Minhe Livestock reported a 7.75% month-on-month increase in sales revenue from commodity chick sales in November [15] - Xuelong Group plans to invest 100 million yuan to establish a wholly-owned subsidiary for vertical integration in the aluminum and magnesium technology sector [16] - Shengnong Development reported a 15.77% year-on-year increase in sales revenue in November, with significant growth in both poultry and processed meat products [17] Group 5 - Xingyu Co., Ltd. plans to repurchase shares worth 200 million to 300 million yuan for employee stock ownership plans [18] - Quan Chai Power intends to use 50 million yuan of idle funds to purchase structured deposit products [19] - Shibei High-tech appointed Zhao Junhong as the new deputy general manager [20] Group 6 - Fuan Pharmaceutical's subsidiary received a drug registration certificate for injectable isavuconazole, expanding its anti-infection product line [21] - Xiaoming Co. reported a 49.73% year-on-year decline in chicken product sales revenue in November [22] - Baiao Chemical adjusted its share repurchase price ceiling to no more than 48.95 yuan per share [23] Group 7 - Hefei China reported a 26.02% year-on-year decline in consolidated revenue for the first 11 months [24] - Laimei Pharmaceutical's subsidiary received medical device registration certificates for two endoscope products [25][26] - Xiantan Co. reported an 11.63% year-on-year increase in chicken product sales revenue in November [27] Group 8 - Qilin Security received government subsidies totaling 5.4014 million yuan [28] - Blue Sky Gas's controlling shareholder's 30.9134 million shares were judicially frozen, accounting for 4.33% of the total share capital [29] - Tieke Railway signed a contract for high-speed railway fasteners worth 654 million yuan, accounting for 41.08% of the company's projected revenue for 2024 [30] Group 9 - David Medical's electric surgical table received a medical device registration certificate [31] - Zhendong Pharmaceutical's affiliate's core product new drug application was accepted by the CDE [32] - Shanghai Pharmaceutical's apple acid sitagliptin tablet application for market approval was granted by the National Medical Products Administration [33] Group 10 - Nanjiao Food reported a 1.14% year-on-year increase in consolidated revenue for November [34]

New Stock Listings - Baiaosaitu (688796) listed at an issue price of 26.68 on December 10, 2025[1] - Quanyin Gaoke (300087) has a tender offer period from December 4, 2025, to January 5, 2026[1] - Tiangong Co. (605255) has a tender offer period from November 20, 2025, to December 19, 2025[1] Delisting and Trading Alerts - ST Guangdao (920680) enters the delisting arrangement period starting December 11, 2025[1] - ST Suwu (600200) has 13 trading days remaining until the last trading day[1] Market Volatility - Hai Xin Food (002702) reported severe abnormal fluctuations[1] - Anji Food (603696) and other companies are under observation for abnormal trading activities[2] Additional Announcements - Multiple companies including Dongbai Group (600693) and Nanjing Business Travel (600250) have recent announcements linked to their stock codes[1] - Various companies are linked to announcements regarding abnormal fluctuations and trading activities[3]

Market Overview - As of December 10, the Shanghai Composite Index closed at 3900.50 points, down by 9.03 points, a decrease of 0.23% [1] - The Shenzhen Component Index closed at 13316.42 points, up by 39.06 points, an increase of 0.29% [1] - The ChiNext Index closed at 3209.00 points, down by 0.60 points, a decrease of 0.02% [1] Trading Activity - A total of 93 A-shares had a turnover rate exceeding 20% on December 10 [1] - Notable stocks with high turnover rates included: - C Baiao (688796) with a turnover rate of 75.80% and a price increase of 146.63% [1] - De Yi Culture (300640) with a turnover rate of 57.78% and a price increase of 9.88% [1] - Longzhou Co. (002682) with a turnover rate of 55.52% and a price increase of 9.96% [1] - C Moore-U (688795) with a turnover rate of 51.93% and a price increase of 16.98% [1] - Shen Nong Agriculture (300189) with a turnover rate of 51.33% and a price increase of 20.07% [1] Individual Stock Performance - C Baiao (688796) closed at 65.80 yuan, showing a significant increase [1] - De Yi Culture (300640) closed at 9.79 yuan, reflecting a positive performance [1] - Longzhou Co. (002682) closed at 10.49 yuan, also showing a positive trend [1] - C Moore-U (688795) closed at 735.00 yuan, indicating strong market interest [1] - Shen Nong Agriculture (300189) closed at 6.88 yuan, demonstrating a solid increase [1]

合富（中国）医疗科技股份有限公司 证券简称：合富中国 证券代码：603122 合富（中国）医疗科技股份有限公司 2025 年第二次临时股东会 会议资料 2025 年 12 月 19 日 合富（中国）医疗科技股份有限公司 目录 | 2025 | 年第二次临时股东会会议须知 2 | | --- | --- | | 2025 | 年第二次临时股东会会议议程 3 | | 2025 | 年第二次临时股东会会议议案 4 | | | 议案一：《关于全资子公司向关联方销售设备的日常关联交易议案》 4 | 1 合富（中国）医疗科技股份有限公司 2025 年第二次临时股东会会议须知 为维护广大投资者的合法权益，保障股东在本次股东会期间依法行使权利， 根据《中华人民共和国公司法》（以下简称"《公司法》"）、中国证监会《上 市公司股东会规则》和合富（中国）医疗科技股份有限公司（以下简称"公司"） 《股东会议事规则》等有关规定，特制定本会议须知： 一、公司负责本次股东会的议程安排和会务工作，出席会议人员应当听从公 司工作人员安排，共同维护好会议秩序。 二、为保证股东会的正常秩序，除出席会议的股东或者股东代理人、董事、 董事会秘书、其他 ...

证券代码：603122 证券简称：合富中国 公告编号：临 2025-067 1 公司 2025 年 1-11 月合并营业收入人民币 62,816.78 万元，较去年同期下降 26.02%。 特此公告。 合富（中国）医疗科技股份有限公司董事会 2025 年 12 月 11 日 合富（中国）医疗科技股份有限公司 2025 年 1-11 月累计营业收入简报 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 合富（中国）医疗科技股份有限公司（以下简称"公司"）之间接控股股东 合富医疗控股股份有限公司（以下简称"合富控股"）为台湾地区证券柜台买 卖中心上柜公司，合富控股需按照台湾证券交易所相关规定，每月披露营业收 入数据。为使 A 股投资者能够及时了解公司的经营情况，本公司亦同步在上海 证券交易所指定的信息披露媒体《上海证券报》、《中国证券报》、《证券时报》、 《证券日报》和上海证券交易所网站（http://www.sse.com.cn）上披露本公司 营业收入。本简报为初步核算数据，未经会计师事务所审计或审阅，最终数据 以公司定期报告为准 ...

Group 1 - The core point of the article is that HeFu China (603122.SH) reported a consolidated revenue of RMB 628 million for the period from January to November, which represents a decline of 26.02% compared to the same period last year [1]